Skip to main content
Premium Trial:

Request an Annual Quote

Sygnis Licenses Amplification Buffer to Qiagen

NEW YORK (GenomeWeb News) – Sygnis Pharma today said that it has licensed to Qiagen rights to distribute a new amplification buffer for isothermal amplification.

Sygnis, which is based in both Madrid, Spain and Heidelberg, Germany, said that the new buffer, which is used in isothermal amplification, was developed in the lab of Margarita Salas at the Center for Molecular Biology - Severo Ochoa, Autonomous University of Madrid/ Spanish National Research Council (CSIC). Terms of the agreement were not disclosed.

The deal is the second signed between Sygnis and Qiagen over the past year. Last July, Sygnis inked an exclusive global license with Qiagen for distribution of its polymerase QualiPhi, an updated version of the phi 29 DNA polymerase.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.